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TRANSBOUNDARY MOVEMENTS OF GENETICALLY MODIFIED ORGANISMS 
AND THE CARTAGENA PROTOCOL: KEY ISSUES AND CONCERNS 
OJ Lim Tung 
1 Introduction 
One of the first attempts1 to legislate on international rules on biotechnology2 goes 
back to the controversial3 article 19 of the United Nations Convention on Biological 
Diversity4 "(hereafter the CBD)" in 1992. The CBD did not provide for a biosafety 
mechanism per se due to there being disagreements over its content and scope.5 
Even though biotechnological applications were not regulated as such at the 
international level in the 1990s, the transboundary movements of genetically 
modified organisms (GMOs) had already started with bulk shipments of agricultural 
products6 and biopharmaceuticals.7 Only with the Cartagena Protocol on Safety of 
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1  Apart from the then European Community’s relevant directives. See EC Directive 90/220/EEC (23 
April 1990) on the deliberate release into the environment of genetically modified organisms and 
EC Directive 90/219/EEC (23 April 1990) on the contained use of genetically modified micro-
organisms. In 1976, before the publication of the European Community's directives, the United 
States (US) had established research guidelines elaborated upon by the National Institute of 
Health (NIH) for their grant recipients. These were adopted by other government agencies as 
well as private industry and a coordinated framework was published in 1986 by the Office of 
Science and Technology Policy. See Kirsch 2002 Int'l & Comp Envtl L 22. 
2  Biotechnology is described by Agenda 21 as "a set of enabling techniques for bringing about 
specific man-made changes in deoxyribonucleic acid (DNA) or genetic material in plants, animals 
and microbial systems." See para 16.1 Agenda 21 Report of the UN Conference on Environment 
and Development UN Doc A/CONF.151/21 (1992); The insertion of a specified protein chain 
(gene) into the DNA of another organism creating a GMO. Kirsch 2002 Int'l & Comp Envtl L 21. 
3  Views differed on the need to regulate genetically modified (GM) crops (Schnier 2001 Fordham 
Envtl LJ 385) and the need for internationally agreed rules on biosafety (Mackenzie et al 
Explanatory Guide 2). 
4  United Nations Conference on Environment and Development Convention on Biological Diversity 
5 June 1992 UN Doc UNEP/Bio.Div/N7-INC.S/4 reprinted in 31 ILM 818. 
5  Street 2001 Env L Rev 250. 
6  Mahieu Le droit de la société de l’alimentation 252; Lim Tung L’encadrement juridique 
international des mouvements transfrontières des OGM 35. While the World Trade Organisation 
(WTO) agreements regulate international trade, they were not concluded specifically to regulate 
GMOs. See part 4 of this paper. 
7  For instance, plants may be genetically modified in such a way that they produce vaccines which 
can be administered by eating the crop. Nuffield Council on Bioethics The Use of Genetically 
Modified Crops 42-43; Le Gac L'encadrement juridique communautaire 63. In 2002 the market 
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Transboundary Movement of Living Modified Organisms8 (LMOs) "(hereafter the 
Cartagena Protocol)" to the CBD in 2000 were the safe transfer, handling and use of 
LMOs (such as genetically engineered plants, animals, and microbes) across borders 
at last catered for, even though the protocol did not include the broader categories 
of GMOs. The protocol provides for an international biosafety framework for the 
transboundary movements of LMOs but there are still key issues in contention.9 
Negotiations on the regulation of biotechnology were fraught with compromise 
between ensuring the sustainable uses of biotechnology on the one hand, and 
environmental and health concerns on the other hand.10 From the beginning there 
was a lack of consensus on the scope of the GMOs to be covered, the scope of the 
informed consent procedure prior to a transboundary movement, and identification 
and traceability issues. However, there has been some progress on liability and 
redress with regard to damage resulting from the transboundary movements of 
LMOs with the adoption of the Nagoya-Kuala Lumpur Supplementary Protocol on 
Liability and Redress11 "(hereafter the Nagoya SP)" to the Cartagena Protocol. There 
are also concerns on the harmonisation of national biosafety regulation, risk 
                                                                                                                          
for biopharmaceuticals was valued at US$400 billion, and its value has doubled ten years later. 
Ferraud-Ciandet N Protection de la santé 150. 
8  Cartagena Protocol on Biosafety to the Convention on Biological Diversity (2000); Redick 2007 
Colo J Int'l Envtl L & Pol'y 51. The Cartagena Protocol covers only LMOs (products of modern 
biotechnology which are capable of replication) instead of GMOs, due to a lack of consensus on 
the scope of the products to be covered by this protocol. An LMO means any living organism that 
possesses a novel combination of genetic material obtained through the use of modern 
biotechnology (art 3(g) Cartagena Protocol) and is capable of transferring or replicating genetic 
material. LMOs can be considered as a sub-group of GMOs according to the Food and Agriculture 
Organisation (FAO) (see FAO 2004 www.fao.org/newsroom/fr/news/2004/43684/index.html).  
9  Oliva 2002 Int'l Legal Persp 24. 
10 Redick 2007 Colo J Int'l Envtl L & Pol'y 62. 
11 See the Nagoya SP (adopted on 15 October 2010) available at 
http://bch.cbd.int/protocol/NKL_text.shtml; During the negotiation of the Cartagena Protocol, 
there was no consensus on the issue of liability and redress for damage resulting from the 
transboundary movements of LMOs, and only a 27 was included in this biosafety protocol. The 
Nagoya SP is a positive input to the international legal framework recognising that biodiversity 
may be threatened by damage resulting from transboundary movements of LMOs. It merely 
gives general guidelines to States parties on the elaboration of domestic regimes for liability and 
redress and is considered to be a set of administrative measures that States parties would have 
to implement. The Nagoya SP does not set up an international regime on liability and redress. 
Basic concepts that are relevant to the subject of liability and redress are left to States parties to 
address (such as the standard of liability, the concept of damage, the types of damage which can 
be compensated for, and evidence of the causal link between the damage and the particular 
GMO). By August 2013 this protocol had only 54 signatories, whereas it needs to be ratified by 
50 States parties to enter into force. See Convention on Biological Diversity date unknown 
http://bch.cbd.int/protocol/parties/#tab=1. 
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assessment and risk management standards, the interpretation of socio-economic 
considerations, the monitoring of compliance with the provisions of the Cartagena 
Protocol and the settlement of GMO-related disputes. The Conference of Parties 
(COP) is called to regularly assess the effectiveness of the protocol12 and to discuss 
opportunities to improve the regulation of the transboundary movements of GMOs, 
but consensus is needed among States parties on controversial issues before any 
change can be brought. This paper discusses the scope of the GMOs covered by the 
Cartagena Protocol, and identification and traceability issues, and highlights 
concerns about the harmonisation of national biosafety regulation, risk assessment 
and risk management aspects, the interpretation of socio-economic considerations, 
the implementation of the protocol’s obligations and GMO-related dispute 
settlement.   
2 The scope of GMOs covered by the Cartagena Protocol  
To produce an agreement acceptable to all the major negotiating groups13 and the 
multilateral trading system, a much weaker protocol was concluded. Only minimum 
standards of regulation for the transboundary movements of LMOs that may have an 
adverse effect on the conservation and sustainable use of biological diversity are 
                                        
12  See a 35 Cartagena Protocol. The COP serving as the meeting of the parties to this protocol shall 
undertake, five years after the entry into force of this protocol and at least every five years 
thereafter, an evaluation of the effectiveness of the protocol, including an assessment of its 
procedures and annexes. 
13  There were 5 different groups with similar positions negotiating for major issues among the 135 
countries. The "Like-minded group" included all the developing countries (except Argentina, Chile 
and Uruguay) and was in favour of a strong biosafety protocol and the regulation of commodities 
with prior consent before shipments were allowed, as well as a well-documented identification of 
GMOs and liability and redress provisions. Zarrilli International Trade in GMOs and GM Products 
58. The "Miami group" (the US, Canada, Argentina, Chile, Uruguay) consisted of the largest grain 
commodity and GM exporting countries (backed by the biotechnological industry) and wanted a 
biosafety protocol which would not affect the international trade of GMOs, an exclusion of 
commodities from the advance informed agreement (AIA) procedure and a saving clause so that 
the biosafety protocol would not undermine the application of trade agreements. The European 
Union (EU) was in favour of a biosafety mechanism which would include all categories of GMOs 
and the precautionary principle to protect human health. The "Compromise group" (such as 
Switzerland, Korea, Norway and New Zealand), which claimed to be acting as a facilitator, and 
the "Central and Eastern European Group" (which acted like the Like-minded group) were the 
smallest negotiating groups. Schnier 2001 Fordham Envtl LJ 403-405. In 2012 some of the 
developing countries of the Like-minded group are counted as the biggest GM crop exporters and 
are among the 10 top producers of GM crops (eg China, India, South Africa). 
OJ LIM TUNG  PER / PELJ 2014(17)5 
1743 
provided in this protocol,14 while the scope of the advance informed agreement (AIA) 
procedure is limited.15 
2.1 The limited scope of GMOs covered 
Since an inflexible level of regulation covering all GMOs was considered as impeding 
innovative technology16 during the negotiations on the Cartagena Protocol,17 the 
term "LMOs" was agreed upon. Consequently, broader categories of GMOs are not 
covered by this protocol. Its scope is limited to LMOs that may have an adverse 
impact on biological diversity and therefore excludes LMOs those that have been 
processed and that are therefore not capable of transferring or replicating genetic 
material.18 It should be noted, however, that domestic legislation19 in different parts 
                                        
14  Street 2001 Env L Rev 249. 
15  The AIA is the main procedure for prior consent by the State of import before the first intentional 
transboundary movement of LMOs is undertaken (a 7 Cartagena Protocol). 
16  Redick 2007 Colo J Int'l Envtl L & Pol'y 64. 
17 Negotiators took almost one year to agree on the definition and the scope of GMOs to be 
covered by this protocol (Jacob 2001 Transnat'l Law 83; Glass 2001 Nw J Int'l L & Bus 493); 
Kohm 2009 UCLA J Envtl L & Pol'y 146-147. 
18   LMOs which have been processed (for instance, GM tomato sauce) cannot reproduce 
themselves, unlike LMOs which have not been processed, such as GM tomatoes. However, the 
processed LMOs may have adverse effects on human health (Buechle 2001 Ind J Global Legal 
Studies 286). More than 90% of GM goods (especially commodities) are thus not covered by this 
protocol. Schnier 2001 Fordham Envtl LJ 414. 
19  The following domestic legislation refers to GMOs and not LMOs. For instance, according to a 
5(2) of the Swiss Federal Law relating to Non-Human Gene Technology "(hereafter the Swiss 
FLNHGT)" a GMO is any organism in which the genetic material has been altered in a way that 
does not occur under natural conditions by crossing or natural recombination (the Swiss Federal 
Law relating to Non-Human Gene Technology Recueil Systématique 814.91). The French 
definition of a GMO is an organism whose genetic material has been modified other than by 
reproduction or natural combination (a L 531-1-2° of the French Code of Environmental Law). S 
10 of the Australian Gene Technology Act "(hereafter the AGTA)" 169 of 2000 defines a "GMO" 
as an organism that has been modified by gene technology or an organism that has inherited 
particular traits from an organism (the initial organism) being traits that occurred in the initial 
organism because of gene technology or anything declared by the regulations to be a GMO or 
that belongs to a class of things declared by the regulations to be GMOs. The South African 
definition of a GMO refers to an organism, the genes or genetic material of which have been 
modified in a way that does not occur naturally through mating or natural recombination or both, 
and "genetic modification" shall have a corresponding meaning (s 1 (xiii) of the Genetically 
Modified Organisms Act 15 of 1997). A 3 of the Chinese regulations on Safety of Agricultural 
Genetically Modified Organisms "(hereafter the Chinese regulations on biosafety)" refers to 
"agricultural GMOs" as animals, plants, micro-organisms and their products whose genomic 
structures have been modified by genetic engineering technologies for use in agricultural 
production or processing (Chinese regulations on Safety of Agricultural Genetically Modified 
Organisms Decree 304 of 2001). A 3 (V) of the Brazilian biosafety law refers to a GMO as "an 
organism whose genetic material, DNA/RNA has been altered by any genetic engineering 
technique" (Brazil Biosafety Act "(hereafter the BBA)" 11.105 of 2005). However, a 3 of the 
Malaysian biosafety law refers to an LMO (any living organism that possesses a novel 
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of the world and regional instruments20 use the term "GMOs" and their biosafety 
frameworks cover not only LMOs but also broader categories of GMOs. Definitions of 
GMOs in domestic legislation in general do not specify or differentiate GMOs from 
LMOs to the extent that the organism to be genetically manipulated is described as 
an entity capable of replication or reproduction.  
The Cartagena Protocol regulates LMOs differently, depending on whether they are 
to be released into the environment or meant for contained use21 or for direct use as 
food, feed or to be processed (FFPs). One of the most contentious issues during the 
negotiations of this protocol was about the regulation of transboundary movements 
of LMOs intended for direct use as FFPs, which represent a large category of 
agricultural commodities.22 These commodities include shipments of GM grains that 
are intended for use as feed for animals and for processing but can also be used as 
seeds.23 There is, nevertheless, no compliance mechanism as to the final use of 
LMOs declared as FFPs, to the extent that some of them may not be used as 
declared for the purposes of export. The monitoring of the final use of these LMOs 
therefore still needs to be addressed. 
It is also not clear in which categories some LMOs will be regulated under the 
Cartagena Protocol. Nutraceuticals24 do not seem to be governed by this protocol to 
the extent that they cannot be considered solely as foodstuffs or pharmaceuticals 
(for instance, GM rice with added vitamin A). GM crops modified as "edible vaccines" 
                                                                                                                          
combination of genetic material obtained through the use of modern biotechnology) and not a 
GMO (Malaysian Biosafety Act 678 of 2007). A 104 of the Canadian law on environmental 
protection (Canadian Protection of the Environment Act  "(hereafter the Canadian EPA)" L.C. 
1999, ch 33) refers to a "living organism" as a substance that is an animate product of 
biotechnology. At the regional level, the European definition of a GMO is an organism (any 
biological entity capable of reproduction or to transfer genetic material) of which the genetic 
material has been modified in a way which is not natural or by reproduction and/or natural 
recombination (a 2 of Directive 2001/18/EC on the deliberate release into the environment of 
genetically modified organisms). 
20  EC Regulation 1946/2003 (15 July 2003) on transboundary movement is not limited to LMOs but 
also covers GMOs. 
21  Any operation, undertaken within a facility, installation or other physical structure, which involves 
LMOs that are controlled by specific measures that effectively limit their contact with, and their 
impact on, the external environment (a 3(b) Cartagena Protocol). 
22  Saphen 2001 Mich State Univ-Detroit College L J Int'l L 65. 
23 Zarrilli "International Trade in GMOs" 61. 
24 Nutraceuticals are considered as foodstuffs with additional health value. Manga S-J Le droit du 
commerce international des OGM 9; Kohm 2009 UCLA J Envtl L & Pol'y 153. 
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or "biopharmaceuticals"25 are also not catered for by the provisions of this protocol, 
since they are neither agricultural products as such, nor pharmaceuticals. Whether 
or not transgenic mosquitoes for disease control purposes26 will be considered as 
pharmaceuticals is not clear. GM pigs are being used for organ transplant purposes27 
but the provisions of this protocol do not apply to this category of GMOs. The 
provisions applicable to LMOs in contained use may potentially apply to GM pigs for 
laboratory use28 being transported from one country to another. However, these pigs 
will not be subjected to risk assessment requirements unless the party of transit 
decides to regulate the transport of such LMOs or the State party of import decides 
to subject such LMOs to risk assessment requirements.29  
2.2 The AIA procedure  
The Cartagena Protocol was drafted with the main purpose of addressing the safety 
of transboundary movements of GM crops, and consensus was not reached on the 
need for the application of the AIA procedure for all categories of LMOs covered by 
the protocol. The AIA procedure does not apply to LMOs in transit30 and LMOs 
destined for contained use,31 while a simplified procedure as per article 11 of the 
Cartagena Protocol is applicable for LMOs intended for direct use as FFPs instead of 
                                        
25  Buechle 2001 Ind J Global Legal Studies 319. Those who are in favour of the development of 
"edible vaccines" argue that injected vaccines are expensive and require trained staff for their 
administration as well as constant cooling during transport and storage. Nuffield Council on 
Bioethics The Use of Genetically Modified Crops 42-43.   
26 For instance, mosquitoes containing a transgene for resistance to rodent malaria. 
27  Jones 1988 Food Drug Cosmet LJ 352. 
28  Lawrence 2007 Ecology LQ 263; Moye 2005 NC L Rev 1567. 
29  Mackenzie et al Explanatory Guide 59. 
30  The COP of the Cartagena Protocol merely encourages parties to continue to address issues 
related to the transit of LMOs through their territories using their domestic administrative and 
legal systems within existing regional and international requirements (see the Fifth meeting of 
the COP serving as the meeting of the Parties to the Cartagena Protocol on Biosafety "(hereafter 
COP-MOP5)" with regard to the rights and obligations of parties for the transit of LMOs). Each 
State may regulate the transit of LMOs as per domestic legislation. Eg, South Africa's (SA) transit 
policy was communicated to the BCH, according to which LMOs may transverse the territory of 
SA to another country only if that country confirms its acceptance of the consignment. See the 
Second regular national report on the implementation of the Cartagena Protocol on Biosafety for 
South Africa on the Biosafety Clearing-House Central Portal at Biosafety Clearing-House 2011 
http://bch.cbd.int/database/record.shtml?documentid=102653. 
31  Parties can regulate LMOs destined for contained use in their territories and undertake risk 
assessments before authorising imports (a 6(2) Cartagena Protocol). 
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the more stringent AIA procedure.  LMOs that are pharmaceuticals for people32 and 
are addressed by other relevant international agreements or international 
organisations, do not need to undergo an assessment of risks prior to their import, 
as is required under the AIA procedure. The exclusion of these LMOs from the AIA 
procedure only was a compromise to the extent that the "Miami Group" wanted to 
exclude pharmaceuticals completely from the scope of the Cartagena Protocol. A 
State party has the right to subject all LMOs to a risk assessment prior to the 
approval of an import, but States parties rarely use this right.33 It is argued that the 
AIA procedure should also cover pharmaceuticals for the use of people. While there 
are relevant international agreements under the aegis of the World Health 
Organisation (WHO) that are applicable to pharmaceuticals for people, it should be 
pointed out that many of these agreements deal with human health concerns and do 
not address the environmental and biodiversity impacts of LMOs.34 
The exporter of the LMOs is responsible for seeking consent before proceeding to an 
intentional transboundary movement of LMOs for the first time, but not prior to 
subsequent movements of the same categories of LMOs.35 The Cartagena Protocol 
does not specify if other exporters can rely on this authorisation to export the same 
category of LMOs for the same purposes. It is also important that the validity of the 
authorisation for the first intentional transboundary movement of LMOs be limited to 
                                        
32  Eg micro-organisms that are genetically modified to transmit the hepatitis B vaccine. Mackenzie 
et al Explanatory Guide 55; Saphen 2001 Mich State Univ-Detroit College L J Int'l L 68. 
33  See a 5 Cartagena Protocol. 
34  Mackenzie et al Explanatory Guide 56. See the existing agreements or programmes under the 
aegis of the WHO 2014 www.who.int/countries/fr/index.html. The movement of pharmaceuticals 
intended for people is subject to the "Certification Scheme on Pharmaceutical Products Moving in 
International Commerce" applicable to finished dosage forms of pharmaceutical products 
intended for administration to human beings or to food-producing animals. The competent 
authority of the exporting country of the pharmaceutical will need to notify to its counterpart in 
the country of import that this pharmaceutical has been authorised to be placed on the market 
within its jurisdiction (WHO 2014 www.who.int/countries/fr/index.html). During the negotiations 
of the protocol, many countries initially opposed to exempting pharmaceuticals for people were 
reassured by the incorporation of a risk assessment in this certification mechanism. See WHO 
date unknown www.who.int/medicines/areas/quality_safety/regulation_legislation/certification/ 
en/. See the 1970 Convention for the Mutual Recognition of Inspections in Respect of the 
Manufacture of Pharmaceutical Products "(hereafter the Pharmaceutical Inspections 
Convention)". Biopharming (the genetic engineering of plants to grow pharmaceuticals, 
antibodies and industrial enzymes) poses more serious risks to human health and the 
environment than crops intended for consumption. Richmond 2006 Pac Rim L & Pol'y J 585. 
35  Kameri-Mbote 2002 RECIEL 63.  
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a period of five years, for instance, subject to the level of scientific knowledge on the 
adverse impacts of GMOs. It could also be required that the exporter of these LMOs 
completes another authorisation procedure before proceeding to an intentional 
transboundary movement if new scientific information on these particular LMOs is 
available before this period. The need for an AIA implies that the exporter needs to 
conduct a risk assessment with regard to the LMOs to be exported, whereas other 
simplified procedures36 do not require a risk assessment. If an AIA is not applicable 
to a category of LMOs, the country of import has nevertheless the discretion to 
request a risk assessment prior to approving the import of this category of LMOs. 
However one could say that not all countries of import (especially developing 
countries) have the necessary technical and financial capacity to undertake risk 
assessments, and countries of export should provide a risk assessment before 
authorisation.  
Simplified procedures apply to LMOs that are considered less dangerous for the 
environment to the extent that they cannot transfer or replicate their genetic 
material, and no risk assessment is required for the approval of these procedures. 
These procedures are not as stringent as the AIA procedure and can be considered 
as a compromise to the scope of the application of the AIA. Article 11 of the protocol 
provides for a simplified procedure which is completed through written notification to 
parties through the Biosafety Clearing House (BCH). If the State of import decides 
that the import of a specific category of LMOs for direct use as FFPs will be allowed, 
only a notice needs to be communicated within 15 days to the BCH as per annexure 
II of the Cartagena Protocol. For LMOs intended for direct use as FFPs, only 
developed countries have obligations to put in place domestic regulatory 
frameworks. Developing countries including those with economies in transition need 
to take decisions based on risk assessments only within a predicted framework.37 
Although an AIA procedure is not required by the Cartagena Protocol regarding 
                                        
36  See aa 11 and 13 Cartagena Protocol. The COP of the Cartagena Protocol is also competent to 
consider particular categories of LMOs as safe LMOs and consequently to exempt them from the 
AIA procedure. 
37  Kameri-Mbote 2002 RECIEL 62. 
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imported agricultural commodities, some countries may require field trials38 before 
approving the import of GM agricultural commodities. Article 13 of the protocol 
provides for a simplified procedure allowing States to export LMOs without a written 
permit if the importing party consents,39 provided all adequate measures have been 
taken. The country of import may inform the BCH about cases in which an 
intentional transboundary movement may take place at the same time as the 
transboundary movement is notified to the Party of import. The country of import 
may also inform the BCH about LMOs considered as not hazardous, which are to be 
exempted from the AIA procedure. 
3 Identification and traceability issues 
The traceability of GM products is the backbone of biosafety regulation and it is in 
line with basic sanitary requirements and the requirement of transparency of 
methods of production.40 Tracing back GM products through the application of a 
general labelling system41 was heavily discussed during the negotiations of the 
Cartagena Protocol. On the one hand, the "Miami Group" and the United States (US) 
wanted to avoid the segregation of LMOs and labelling requirements. On the other 
hand, the European Union (EU) wanted GM plants, bacteria, animals or agricultural 
or food products to be labelled on the basis of health and environmental grounds as 
well as to allow for better consumer choice. Vocal debates on the labelling of LMOs 
resulted in compromises as to whether they should be labelled and which ones 
should actually be labelled. This part discusses the need for an international 
identification system for GM products and the harmonisation of thresholds of GM 
content for non-GM products at the international level. 
                                        
38  For instance, the Republic of Korea approved ten biotech events for food and feed use only, but 
required field trials for these commodities. Redick 2007 Colo J Int'l Envtl L & Pol'y 97-98. 
39  Kameri-Mbote 2002 RECIEL 64. 
40  Granjou La gestion des risques 311. The Codex Alimentarius Commission (a food standards -
setting commission under the aegis of the FAO and the WHO) defines "traceability" as "the ability 
to follow the movement of a food through specified stage(s) of production, processing and 
distribution." See FAO date unknown www.fao.org/ag/againfo/themes/en/meat/ 
quality_trace.html. Traceability in general is the ability to follow the movement of a product from 
its first stage of production to the consumer. 
41  Maljean-Dubois "La Régulation du Commerce International" 36-37; Tracy 1999 Buff Envtl LJ 137. 
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3.1 An international identification system for GM products   
An international identification system42 is needed so that a product can be identified 
from its first stage of production to the stage where it reaches the consumer. 
However, it may not be an easy task to achieve over the whole of the production 
process without rigorous management. Being able to trace back GM products in a 
food chain facilitates precise labelling, identification, detection and monitoring of 
their effects on the environment and human health. An efficient traceability 
mechanism needs to be harmonised43 at all stages of the production of GMOs, with 
appropriate risk management measures in order to facilitate the withdrawal of 
hazardous products44 from the market. During the negotiations of the Cartagena 
Protocol, the EU wanted to extend the traceability debate on food standards while 
the US was of the opinion that it is the Committee of the Codex Alimentarius that is 
competent for such an issue.45 However, at the international level the Codex 
Alimentarius Commission46 does not consider traceability as a priority but merely as 
one of the tools to be used for the inspection and accreditation/certification of 
foodstuffs.47 This commission did consider labelling issues pertaining to GM food that 
would allow consumers an informed choice, but has not taken a stand between the 
                                        
42  Mansour and Key 2004 Int'l Law 55. 
43  There is a diversity of labelling standards in different countries. For instance, no mandatory 
labelling is required for GM products in the US and in Canada (Strauss 2006 International Lawyer 
98). Mandatory labelling is required for products containing 1% GM content in Australia and New 
Zealand (see Food Standards Australia New Zealand GM Food Labelling, Compton 2003 Pace Int'l 
L Rev 385), for Saudi Arabia and for China (Appleton 1999-2000 New York UELJ  568). The 
labelling threshold for GM products is 0.9% for the European Union (see Europa Summary of EU 
Legislation http://europa.eu/legislation_summaries/environment/nature_and_biodiversity/l21170 
_en.htm and Regulation 1830/2003 of the European Parliament and of the Council of 22 
September 2003 concerning the traceability and labelling of genetically modified organisms and 
the traceability of food and feed products produced from genetically modified organisms and 
amending Directive 2001/18/EC Official Journal L 268/24 18.10.2003), 3% for Korea (Compton 
2003 Pace Int'l L Rev 387) and 5% for Japan (Coffield 2000 Canada-US LJ 27) and for South 
Africa (see the South African Labelling Regulations (GN R293 in GG 34180  of 1 April 2011) in 
terms of s 120(1) of the Consumer Protection Act). 
44  Granjou La Gestion des Risques 339; Wal 1997 Rev Fr Allergol 332; A 1 of EC Regulation 
1830/2003 concerning the traceability and labelling of genetically modified organisms and the 
traceability of food and feed products produced from genetically modified organisms and 
amending Directive 2001/18/EC. 
45  See FAO-WHO 2002 www.who.int/foodsafety/codex/en/codex_eval_report_en.pdf. See Codex 
Alimentarius date unknown www.codexalimentarius.org/committees-and-task-forces/en/. 
46  The Codex Alimentarius is also one of the WTO’s reference bodies on food/feed safety including 
traceability systems. Redick 2007 Colo J Int'l Envtl L & Pol'y 61; Dufour, Barsalou and Mackay 
2006 Cahiers de Droit 485-486.  
47  Codex Alimentarius Commission Principles for Traceability 1-3. 
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adoption of product-based labelling or a process of production-based labelling.48 The 
tolerance of the adventitious presence of GM content in imported products was also 
lengthily discussed, as well as the standards and guidelines for the assessment of 
GM food. However, no stand has been taken49 on these issues due to a lack of 
consensus.  
The Cartagena Protocol was finalised with compromises on the labelling of LMOs 
subject to transboundary movements. It states merely that States parties should 
take measures to require identification documentation to accompany shipments with 
LMOs to be used directly as FFPs. The shipments must be clearly identified as goods 
that "may contain GMOs" and it must be stated that they will not be introduced into 
the environment. More specific and detailed requirements pertaining to the 
identification of these LMOs50 were meant to be decided by the COP convened two 
years after the entry into force of the Cartagena Protocol, in consultation with other 
relevant international organisations. In 2006, States parties to the Cartagena 
Protocol in Curitiba (Brazil) discussed the designation to be used on the products or 
on commercial invoices during shipping and the "may contain LMOs" designation 
succeeded after intense negotiations.51 States parties were encouraged52 to 
implement laws that mandate the disclosure of biotech crop inputs where the 
identity of the traits53 is "known through means such as identity preservation 
systems".54 Where the identity of the traits is known (for instance, Roundup Ready 
                                        
48  For years, the Committee of the Codex Alimentarius on the Labelling of foodstuffs presided by 
Canada tried to negotiate for a solution to the labelling of GM foods to no avail. Buechle 2001 
Ind J Global Legal Studies 311-312. 
49  Two meetings in March 2000 and 2001 failed to reach consensus on traceability issues due to 
conflicts between the EU and the US. Maljean-Dubois "La Régulation du Commerce 
International" 51-52; Lim Tung L’encadrement juridique international des mouvements 
transfrontières des OGM 15. 
50 See a 18(2)(a) Cartagena Protocol. 
51  See the Curitiba Consensus in March 2006 (International Institute for Sustainable Development 
et al 2006 www.iisd.ca/biodiv/bs-copmop3). 
52  Secretariat of the CBD Decisions of COP-MOP3 2007.  
53  Each trait in a biotech crop (eg resistance to a particular herbicide or virus) has been given 
unique identifiers for the genetic transformation event they are known to contain by means of 
the identifying information elaborated by the OECD. It has a unique identification system known 
as the OECD Unique Identifier for Transgenic Plants which the BCH approves and lists as suitable 
for planting or import and suitable for food or feed. OECD date unknown 
bch.biodiv.org/organisms/uids.shtml.  
54 This term requires interpretation as to its meaning in the context of existing agricultural 
management practices, but for certified seed production it means procedures to preserve the 
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Soybeans), there would be shipment disclosure. But where the identity of the traits 
is not known, parties are not requested to enact legislation mandating lists of all 
possible traits55 that a shipment "may contain" upon arrival in port. The importing 
party has the discretion to decide what will be requested in the list56 and the 
appropriate procedure to be completed. Paragraphs 2 (b) and (c) of article 18 of the 
Cartagena Protocol also place obligations on parties to take measures to require 
more precision on the documentation accompanying LMOs destined for contained 
use and LMOs for intentional introduction into the environment and any other LMO 
within the scope of the protocol. Accompanying documents need to clearly identify 
them as LMOs, to specify any requirements for their safe handling, storage, 
transport and use, and to provide other specific information. There is no consensus 
yet on the need for and modalities of developing standards with regard to 
identification, handling, packaging and transport practices pertaining to these 
LMOs.57 The sixth meeting of the COP to the CBD serving as the Meeting of the 
Parties to the Cartagena Protocol on Biosafety "(hereafter COP-MOP6)" mainly 
requested parties to continue to use a commercial invoice or other documents 
required or utilised by existing documentation systems.58   
An international identification system is necessary, with labelling requirements for 
GM products, to be able to segregate GM products from non-GM ones and avoid 
                                                                                                                          
purity level of a seed product.  
55  In practice, grain exporters find it costly to mandate a list of all possible traits since this would 
involve testing, trade disruption, and efforts to preserve products from adventitious presence of 
GM content. Redick 2007 Colo J Int'l Envtl L & Pol'y 74. 
56  Only a few countries such as Mexico and Japan have listed their approvals of traits at the BCH in 
accordance with a 11, but there might be inadvertent commingling at the time of import (Redick 
2007 Colo J Int'l Envtl L & Pol'y 75). 
57  The Secretariat of the CBD had the task to explore possibilities to strengthen inter-organisational 
cooperation (through inter-agency administrative agreements) regarding the creation, under the 
umbrella of the World Customs Organisation, of a new tariff position for LMOs and their different 
uses (for direct use as FFPs or contained use or for intentional introduction into the 
environment). Another possibility was to share the International Portal on Food Safety, Animal 
and Plant Health with the FAO with a view to storing all available information on one website. 
The Secretariat of the CBD also had to advise the UN Committee of Experts on the Transport of 
Dangerous Goods about LMO risks, and eventually, propose some adaptations to the UN Model 
Regulations. See Secretariat of the CBD Analysis of information on standards relevant to the 
handling, transport, packaging and identification of LMOs COP-MOP6. 
58  Parties can also use the documentation required by domestic regulatory and/or administrative 
frameworks. See Secretariat of the CBD 2012 www.iisd.ca/biodiv/bs-copmop6/.  
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mistakes59 in handling shipments during transboundary movement. Without an 
international identification system and segregation procedures for GM and non-GM 
products, there is no effective traceability of GM products. It is also important for an 
international traceability system to ensure that there is transmission and 
conservation of information on GM products, as well as a unique identification code60 
to be used at each stage of production until the products are placed on the market. 
All required documents, labels, standardised delivery notes recorded in official 
registers and identification codes would need to be transmitted in writing by the 
different operators involved at each stage of production.61 Due to a lack of 
consensus, the Cartagena Protocol does not indicate any requirement for the 
segregation of LMOs for the purposes of transboundary movement. Mandatory GM 
food labelling at the international level may still be opposed presently by the 
biotechnology industry or its advocates in the food industry for fear of stigmatising 
GM foods.62  
3.2 Harmonisation of labelling thresholds for GM products 
Due to a lack of consensus on the need for labelling GM products, an international 
labelling threshold could not be determined.63 States have different approaches on 
                                        
59  In the US, corn intended to be used as animal feed got mixed up with food for human 
consumption. Consequently the corn producer had to withdraw all the products; Buechle 2001 
Ind J Global Legal Studies 159; Beebe 2004 WMELPR 511; Bratspies 2003 WMELPR 593; 
Hutchinson 2008 San Diego Int'l LJ 236; Hamilton 2005 Wash U JL & Pol'y 46; Nelson 2002 
Drake JAL 242; Woodsmith 2003 San Joaquin ALR 210; Isham 2006 Journal of Food Law & Policy 
100; Winn 1999 Food & Drug LJ 670. However, where bulk processing systems are used for 
shipping of grains, the identification of each biotech trait in a shipment that contains various 
biotech traits will pose challenges, if ever there are international segregation rules on shipments. 
UNEP 2006 www.biodiv.org/doc/meetings/bs/mop-03/official/mop-03-15-en.pdf. 
60  The term "unique identifier" means a simple numeric or alphanumeric code which serves to 
identify a GMO on the basis of the authorised transformation event from which it was developed 
and providing the means to retrieve specific information pertinent to that GMO. See a 3(4) EC 
Regulation 1830/2003. The OECD has not yet developed a unique identifier for other types of 
GMOs such as micro-organisms or animals. See Secretariat of the CBD Analysis of information on 
standards relevant to the handling, transport, packaging and identification of LMOs COP-MOP6. 
61  EC Regulation 1830/2003 provides for a traceability mechanism for two categories of products, 
namely products that consist in GMOs or which contain GMOs, and feed intended for human 
consumption and GM animal feed. Operators using or handling GM products need to transmit 
and retain during 5 years relevant information (that the product contains or consists of a GMO) 
at each stage of its introduction on the market. See a 4(1) of this regulation. 
62  Schoenbaum 2000 ICLQ 37. 
63  All GM food labelling should use predetermined thresholds, as it is not possible to ensure zero 
GM in a product once GMOs are present in the production system. Bullock 2002 Food Policy 81-
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traceability standards which need to be harmonised with sound detection methods 
and a harmonised minimum threshold of the tolerance of GM content.64 In practice, 
the threshold of tolerance of GM content is often equivalent to the labelling 
requirements of GMOs or the adventitious presence of GM content.65  
A lack of harmonised thresholds undoubtedly has an impact on the organic products’ 
industry. Organic food producers in countries with no tolerance threshold for GM 
content or a higher level of threshold tolerance (for example 5%) may not get 
access to the organic market in countries having a low tolerance threshold (for 
example 1%). However, providing information on the identification of traits at a zero 
tolerance threshold may have technical and practical limitations.66 The reliability or 
accuracy of the lists of traits might be another issue. Seeds tested as negative for 
such a biotech trait may be considered as negative in one country and positive in 
another country. Consequently, an action filed in different countries to seek 
compensation for the contamination of non-GM crops will have different outcomes. 
4 Main concerns about the regulation of biosafety at the international 
level  
In addition to the key issues that have been analysed in this paper, there are 
concerns about the harmonisation of biosafety regulation, the interpretation of socio-
economic considerations, the harmonisation of risk assessment and risk 
management standards, and the monitoring of compliance. This part ends with 
concerns about the likelihood of GMO-related disputes being settled under other 
recourse mechanisms than the CBD dispute settlement mechanism.   
                                                                                                                          
99. 
64  A few examples of different labelling thresholds for GM products are as follows. A 0.9% threshold 
is applicable in the EU and Switzerland; a 1% threshold in Australia, New Zealand and Brazil; and 
a 5% threshold in Japan, SA and Taiwan; while there is no labelling threshold in the US. 
65  EC Regulation 49/2000 allows a de minimis labelling threshold of 1% (for each ingredient 
individually considered) for the accidental content of GM material in non-GM products; Zarrilli 
"International Trade in GMOs" 50. Japan has a 5% tolerance for approved biotech crops in non-
GM bulk shipments for imported soybeans from the US for non-GM food products. Redick 2007 
Colo J Int'l Envtl L & Pol'y 105-106.  
66 Redick 2007 Colo J Int'l Envtl L & Pol'y 94. 
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4.1 Harmonisation of biosafety regulation  
Since the adoption of the Cartagena Protocol, there has been a noticeable increase 
of countries having biosafety frameworks not necessarily with the same standards. 
In 2002, the Fund for Global Environment adopted an initial strategy with some 
measures to be taken. This strategy was followed in June 2001 by a United Nations 
project of the Environment Programme (UNEP)-Global Environment Facility (GEF)67 
with US$ 39 million to help 100 developing countries to set up national biosafety 
frameworks (NBFs).68 By 2007 more than 130 countries had developed or were in 
the process of developing their NBFs with the support of the GEF. By May 2012, 121 
countries had completed most parts of their NBFs69 and biosafety frameworks can be 
said to be partially or fully in place in most States parties to the protocol. The 
harmonisation of these biosafety frameworks is needed to ensure the safe handling 
of GMOs during transboundary movement in different regions of the world.70 In 2013 
most of the regional groups71 did not have an overarching regional biosafety 
framework as such, although several States within these regional groups may have 
NBFs or draft frameworks.  
                                        
67 This project included a contribution of US$ 6 million for the setting up of NBFs, based on the 
experience and lessons to be learnt from a previous set of pilot projects undertaken in 18 
countries between 1997 and 1999. 
68 The main components of an NBF are a regulatory system set in place to address safety in the 
field of modern biotechnology, an administrative system to handle requests for permits for 
certain activities, a decision-making system that includes risk assessment and management for 
the release of LMOs, and mechanisms for public participation and information. UNEP/GEF 
Building Capacity for the Implementation of the Cartagena Protocol on Biosafety 2002 15. 
69  See UN Environment Programme date unknown www.unep.org/biosafety/National%20Biosafety 
%20frameworks.aspx. The Cartagena Protocol has a total number of 166 States parties. 
70  See national reporting figures. 143 countries out of 163 submitted their second national report 
before 30 September 2011 (CBD 2013 http://bch.cbd.int/protocol/cpb_natreports.shtml). Only 
half of the parties have implemented the core provisions of the protocol with an AIA procedure. 
International Institute for Sustainable Development et al 2012 www.iisd.ca/ 
vol09/enb09585e.html. 
71 The categories of the UN regional groups are the African group (54 members, 28% of UN 
members, 39 NBFs), the Asian Group (53 members, 27% of UN members, 36 NBFs), the Central 
and Eastern Europe Group (23 members, 12% of UN members, 18 NBFs), the Latin America and 
Caribbean Group (GRULAC) (33 members, 17% of UN members, 29 NBFs) and the WEOG 
(Western Europe and other groups) with 15% of UN members) UN Environment Programme date 
unknown www.unep.org/biosafety/National%20Biosafety%20frameworks.aspx. 
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The African region has a Draft African Union Model Law on Safety in Biotechnology72 
which sets higher standards than those of the Cartagena Protocol. This region can 
be said to have been confronted with GMO issues in a special way through GM food 
aid,73 and several countries took a negative stand even in the midst of serious 
national food needs.74 Harmonisation projects75 are also being undertaken by various 
institutions having vested interests in the biotechnological industry, such as the US-
funded Aid Programme for Biosafety Systems in East and West African countries.  
                                        
72 The obligations set out in the Cartagena Protocol did not fully align with national needs and 
priorities of many African countries and even contain some provisions which are considered to be 
forced upon African countries. See Kameri-Mbote 2002 RECIEL 62. The Draft Revised African 
Union model law on Safety in Biotechnology is meant to set standards for the African continent 
subjecting the entire spectrum of GMOs to safety assessments. However these standards serve 
mainly as guidelines to African countries, since this model law on biosafety has not yet been 
finalised. See Draft Revised African Union Model Law on Safety in Biotechnology 2011 
http://hrst.au.int/en/sites/default/files/2011-FinalDraftAMLS-en.pdf. 
73 In 2002, Zambia refused maize offered by the US for health reasons and risks of contamination 
of local varieties of maize, since part of the stock contained GM maize. The government of 
Zimbabwe authorised the entry of GM food aid in July 2002 but requested that the GM maize be 
milled as soon as it arrived to avoid risks of contamination of local varieties. Uganda announced 
that GM agricultural products could be imported but only for consumption and not for agricultural 
purposes. Sudan requested that food aid from the US be certified "non-GM" whilst Angola 
accepted GM food aid only if all the GM cereals were milled before their entry into its territory. 
Zarrilli Le commerce international des OGM 11-12; Hamilton 2005 Wash U JL & Pol'y 41. 
74  In 2006 44 countries in Africa are said to have received food aid from the World Food 
Programme (WFP) and the USAID including GM food or with traces of GM content, mostly in the 
US donations. The WFP has adopted a policy that allows recipient countries to specify whether 
they are prepared to receive food aid contaminated with GMOs. Moola and Munnik GMOs in 
Africa 5. 
75 The West African Regional Biosafety Project was funded by USAID in this region while the 
Economic Community of West African States (ECOWAS) and the Common Market for Eastern and 
Southern Africa (COMESA) are being used as a forum to regulate biosafety with seemingly 
weaker biosafety policies. The African Union’s Biosafety Strategy envisions that Regional 
Economic Communities or bodies will facilitate regional trade and implement the African 
Biosafety Strategy. Cooperation is being sought in a few countries within a region willing to set 
up legislation favourable to the development of GM crops, which would then be used as a 
springboard to reach that particular region in terms of model policies. Although a 23 of the 
Cartagena Protocol encourages public awareness and participation, the target seems to be 
mainly to establish a one-stop regional market for GM seeds without going through a democratic 
debate. The COMESA policy on GM technology has been drafted after the conclusion of a process 
taking nine years, and has been submitted for national consultation. According to this policy, 
once the COMESA has approved the development of a GM crop in one of the Member States, this 
approval will be applicable in these 19 countries. A biosafety map is also being discussed under 
the COMESA for the development of national regulations on GMOs as well as communication 
schemes for the dissemination of information on GMOs. See International Service for the 
Acquisition of Agri-biotech Applications (ISAAA) 2010 www.isaaa.org/kc/cropbiotechupdate/ 
article/default.asp?ID=6828. 
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The Asian region is poised to play a crucial role in determining how widely GM crops 
will be accepted on an international scale.76 It has many developing countries 
struggling to feed their populations, but also includes some of the biggest exporters 
of GM products such as China77 and India, as well as a good agricultural import 
market.78 There seems to be no regional Asian biosafety mechanism yet, but general 
guidelines are available on the release of agriculture-related GMOs under the aegis 
of the Association of South East Asian Nations (ASEAN) Economic Community.79 
Harmonisation strategies are being carried out by private institutions such as the 
International Food Policy Research Institute (IFPRI) for Asian countries.80  
The Latin America and Caribbean Group (GRULAG) has some of the biggest initial 
exporters of GM crops such as Argentina81 and Brazil,82 but no regional biosafety 
mechanism per se. Mexico serves as a centre of origin for maize and key corn 
innovators and does regulate some food safety aspects in relation to GMOs.83  
                                        
76 Richmond 2006 Pac Rim L & Pol'y J 570-571. 
77 China has been using native Chinese genetic resources to improve commercial rice productivity 
with biotech rice, and imports mainly soybeans to feed its population (Redick 2007 Colo J Int'l 
Envtl L & Pol'y 100). According to information submitted to the CBD secretariat on 17 July 2000, 
China has completed the UNEP/GEF project for formulating the national biosafety framework and 
has strengthened legislative and administrative measures for biosafety management, and 
capacity-building in this field. China has regulations on the safety of agricultural GMOs, 
safeguarding human health and the safety of animals, plants and micro-organisms, protecting 
the environment and promoting research on agricultural GMOs (Chinese regulations on 
biosafety).  
78  Malaysia is the 26th largest agricultural export market for the US with respect to GMO soybean 
and corn shipments (valued at US$36 million in 2005) and is considered as an influential voice 
among developing countries and in the Islamic world, with its leadership on "halal issues". The 
year 2005 marked the new National Biotechnology Policy to give impetus to develop the 
biotechnology sector. See USDA Malaysia Biotechnology Annual 2006 3. 
79 See ASEAN 2009 www.asean.org/communities/asean-economic-community/item/asean-
cooperation-in-food-agriculture-and-forestry-major-achievements. 
80  Gruere, Bouët and Mevel Genetically Modified Food and International Trade. 
81  Richmond 2006 Pac Rim L & Pol'y J 578. Argentina’s biosafety regulatory system comprises of 
farming and sanitary rules and administrative laws emanating from the national authority (the 
Secretariat of Agriculture, Livestock, Fisheries and Food) with a detailed system on the 
procedures applicable for the use, release and placing on the market of GMOs of both animal 
and plant origin. Secretariat of Agriculture, Livestock, Fisheries and Food Revision of Argentina’s 
National Biosafety Framework 1-2. 
82 Brazil’s biosafety framework provides for safety standards for GMO-related activities as well as 
biosafety institutions. 
83 See Redick 2007 Colo J Int'l Envtl L & Pol'y 106-107. Mexico is also a State Party to the 
Cartagena Protocol and has made an agreement on the application of a 18(2)(a) with its 
partners of the North American Free Trade Agreement (NAFTA), the trilateral trade bloc 
agreement applicable to North American countries  (the US and Canada) as from 1 January 
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The Central and Eastern Europe (CEE) Group does not have a regional biosafety 
framework, but the UNEP took initiatives for the setting up of appropriate biosafety 
systems with funds from the GEF. The European Federation of Biotechnology and 
the UN Industrial Development Organisation’s Biosafety Information Network and 
Advisory Service (BINAS) have been involved in helping the CEE countries to develop 
regulatory frameworks on biotechnology. In September 1994 a task force for 
regulatory oversight for CEE countries was established with limited success in the 
development of regulatory frameworks within this region.  
The Western Europe and other groups (WEOG) is another UN regional group which 
is composed of countries with individual NBFs, but also has one of the most 
stringent regional biosafety framework for members of the EU. This region also 
includes exporters of GM products such as Canada and Australia,84 while the US is 
mainly an observer.85  
States parties to the Cartagena Protocol can conclude bilateral, regional or 
multilateral agreements or arrangements with States which are not parties to this 
protocol concerning transboundary movements of LMOs.86 Such agreements which 
                                                                                                                          
1994. See NAFTA date unknown www.nafta-sec-alena.org/Default.aspx?tabid=87&language=en-
US. The NAFTA provisions on sanitary and phytosanitary measures recognise NAFTA 
governments’ right to have more stringent measures than the international standard. See article 
713(3) NAFTA. Scientific evidence must be demonstrated and these measures can be maintained 
only on scientific grounds with risk assessments. Risk analysis under NAFTA allows shipments 
designated non-GMO to have up to 5% of approved GM material. The regulations also refer to 
the standards of the WTO reference bodies. Coffield 2000 Can-US LJ 241.  
84  The AGTA consolidates the regulation of GMOs and GM products and provides for an agency 
overseeing all GMO-related issues, namely the Office of the Gene Technology Regulator (OGTR). 
Other committees like the scientific committee, the community committee and an ethics 
committee provide advice to the OGTR and Ministerial Council. Richmond 2006 Pac Rim L & Pol'y 
J 587. 
85 The US is not a member of any regional group but attends meetings of the WEOG as an observer 
and is considered to be a member of that group only for electoral purposes. See UN 2014 
http://www.un.org/Depts/DGACM/RegionalGroups.shtml. There are several administrative 
agencies ensuring that GM agricultural products are safe: the United States Department of 
Agriculture (USDA), the Animal and Plant Health Inspection Service (APHIS) protecting 
agriculture from pests and diseases, the Food and Drug Administration (FDA) governing the 
safety and labelling of drugs, food and feed. The Environment Protection Agency (EPA) ensures 
the safe use of pesticides and herbicides in the environment and the safe use of industrial 
microbes in the environment, while the NIH has guidelines for the laboratory use of GMOs. 
Coffield 2000 Can-US LJ 239. As members of the NAFTA, the US and Canada are subject to the 
provisions of this regional agreement in respect of sanitary and phytosanitary measures. 
86   See a 24 Cartagena Protocol. 
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came into being prior to the protocol or after its coming into force87 should not 
provide a lesser degree of protection, but in practice there does not seem to be any 
compliance mechanism in this matter. Bilateral or multilateral trade agreements are 
said to be used by some industrialised countries as an indirect means to weaken the 
provisions of this protocol.88 
4.2 The interpretation of socio-economic considerations 
The Cartagena Protocol includes socio-economic considerations89 which States 
parties can take into account when reaching a decision on an import of LMOs. 
However, the understanding and scope of socio-economic considerations need to be 
clarified in this protocol. Adequate research and studies are required to fill 
knowledge gaps and to identify specific socio-economic issues related to LMOs. 
Appropriate methods of assessment of socio-economic considerations, particularly 
regarding social and other impacts on indigenous and local communities, are sorely 
needed.90 Consensus should be sought on general guiding principles to be used for 
the consideration of the socio-economic impacts of GMOs, taking into account the 
specific circumstances applicable to States parties. In practice, measures that are 
likely to be considered on the basis of socio-economic grounds would probably run 
the risk of being considered as barriers to trade. The African Centre for Biosafety 
(ACB) initiated discussions with regard to two South-African assessment studies 
submitted to the Secretariat of the Cartagena Protocol, but no light has been shed 
yet on the interpretation of socio-economic considerations.91 However, COP-MOP6 
                                        
87  See a 14 Cartagena Protocol. 
88  Grain 2007 www.infogm.org/spip.php?article3114 84; GRAIN is a non-governmental organisation 
promoting sustainable practices in agriculture. See Grain 2014 www.grain.org. 
89  Considerations arising from the impact of LMOs on the conservation and sustainable use of 
biological diversity, especially with regard to the value of biological diversity for the indigenous 
and local communities. See a 26(1) Cartagena Protocol. 
90  See Centre for International Sustainable Development Law Biosafety Scoping Study 9-11; Oliva 
2002 Int'l Legal Persp 25-26; See Secretariat of the CBD Workshop on socio-economic impacts of 
LMOs 2011. 
91  These two studies highlighted the South African experience regarding the rejection of GM Spunta 
G2 potato for commercial release, GM yeast and grapes for wine production. The failure of the 
governmental massive "Food Production Programme" in the Eastern Cape was also underscored 
in these studies. This Food Production Programme promotes the use of GM maize for small-scale 
farmers. See the study on the "Potential Economic Benefits of a Genetically Modified Tubermoth-
resistant Potato Variety in South Africa: an Ex-Ante Socio-economic Evaluation for Commercial 
Producers" (African Centre for Biosafety 2011 www.acbio.org.za/index.php/gmo-regulatory-
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made a groundbreaking decision by establishing an Ad Hoc Technical Expert Group 
(AHTEG) to develop conceptual clarity on socio-economic considerations with a view 
to developing future guidelines.92  
4.3 Risk assessment and risk management standards  
There is no standard-setting body or a common structured approach to the 
assessment of risks with regard to LMOs which will be subject to transboundary 
movements. Assessment and the management of risks93 need to be carried out in a 
scientifically sound and transparent manner and can take into account expert advice 
as well as guidelines developed by relevant international organisations, but there 
may be conflicts on the standards to be applied.94  
A State party may require the exporter to carry out and bear the costs of a risk 
assessment,95 but not all developing countries have the technical and financial 
capacity to carry out risk assessments. Developing countries will tend to rely on the 
                                                                                                                          
issues/110-south-africa/349-submission-on-socio-economic-considerations) and the study on the 
"Smallholder potato production activities in South Africa: a Socio-economic and Technical 
Assessment of 5 cases in 3 provinces" (African Centre for Biosafety 2011 
www.acbio.org.za/index.php/gmo-regulatory-issues/110-south-africa/349-submission-on-socio-
economic-considerations). 
92  International Institute for Sustainable Development et al 2012 www.iisd.ca/vol09/ 
enb09585e.html. 
93  A risk assessment under this protocol is meant to identify or evaluate the potential adverse 
effects of LMOs on the conservation and sustainable use of biological diversity in the potential 
receiving environment also taking into account risks to human health. The methodology 
described in annex III of the protocol follows the conventional risk assessment paradigm, 
beginning with the identification of a potential hazard, such as the characteristics of an LMO 
which may have an adverse effect on biodiversity. Risks are then characterised based on a 
combined evaluation of the likelihood of adverse effects and the consequences should those 
effects be realised. Risk management pertains to decisions that are made after a risk assessment 
has been made (a 16 of this protocol). A "risk management is the process of identifying, 
evaluating, selecting, and implementing actions to reduce risk to human health and to 
ecosystems." The nature and magnitude of all identified risks are taken into consideration to 
elaborate procedures that can eliminate or decrease these risks. A balancing of risks on the basis 
of scientific evidence needs to be effected with the support of the different actors involved in the 
GM-related activity/transboundary movement of LMOs. 
94  See annexure III (3) Cartagena Protocol. Studies carried out on the effects of GM maize on rats 
by French scientist Séralini were highly criticised by the conclusions of separate and independent 
assessments carried out by the European Food Safety Authority (EFSA) following publication of 
the paper in the journal Food and Chemical Toxicology on 19 September 2012. EFSA Press 
Release; See Séralini G-E et al 2012 Food and Chemical Toxicology 4221-4231. This paper was 
retracted by this journal on the basis of its inconclusiveness in November 2013. See the 
retraction notice to the Séralini study at ScienceDirect 2013 www.sciencedirect.com/ 
science/article/pii/S0278691513008090. 
95  See a 15(3) Cartagena Protocol. 
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exporter’s assessments to a large extent and will have to bring scientific evidence of 
the additional risks they have evaluated. Scientific evidence with regard to risks 
might also be an issue regarding liability procedures. If litigation takes place in the 
exporting country there may be pressure on weaker parties to give up their rights or 
claims.96 A roster of experts97 on biosafety was established in 2000 to provide advice 
to developing countries and countries with economies in transition that are parties to 
the Cartagena Protocol. These biosafety experts also provide support to conduct a 
risk assessment associated with the transboundary movements of LMOs. Technical 
documents have been produced by the AHTEG on Risk Assessment and Risk 
Management after discussions on the risk assessment and risk management of 
GMOs, as well as guidelines on mosquitoes, abiotic stress tolerant plants, and 
stacked genes.98 Although some progress has been made in the assessment and 
management of risks in these areas, there is still room for improvement. There 
should be a balance of legal and socio-economic experts as well as technical experts 
on the roster. The AHTEG recommendations are called to be more specific with 
regard to geographical requirements and long-term assessments should also be 
done. Best practices on biosafety-related expertise, experiences gained and 
challenges met in nominating independent experts need to be shared. A harmonised 
risk assessment and risk management system is sorely needed at the international 
level. Unfortunately a wait-and-see approach99 has affected discussions on risk 
assessment and risk management so far. This has been the case in particular for the 
revised guidance on the risk assessment of LMOs for nationally adapted risk 
assessment approaches.  
                                        
96  Kameri-Mbote 2002 RECIEL 64. 
97  See Decision EM-I/3 on the adoption of the Cartagena Protocol and interim arrangements (CBD 
date unknown https://www.cbd.int/decision/cop/?id=7174). The BCH provides an open-ended 
online expert forum on risk assessment and risk management. A training manual and electronic 
training on the risk assessment of LMOs are available at the BCH Central Portal. See BCH date 
unknown http://bch.cbd.int/. 
98  The Meeting of the Parties (MOP) to the Cartagena Protocol established this expert group to 
develop the support necessary for the assessment of GM fish, trees, insects, algae and micro-
organisms. See COP-MOP 5 in October 2010 in Nagoya. 
99  This approach consists either of gathering more information and reviewing the issue at a later 
stage, or of waiting until there is a problem to trigger a review. See Secretariat of the CBD 2012 
www.iisd.ca/biodiv/bs-copmop6/. 
OJ LIM TUNG  PER / PELJ 2014(17)5 
1761 
4.4 Monitoring of compliance  
The Intergovernmental Committee for the Cartagena Protocol (ICCP) developed 
compliance procedures and mechanisms and a Compliance Committee was 
established during the first meeting of the COP in 2004.100 However, general 
compliance with regard to the implementation of the obligations under the 
Cartagena Protocol101 needs to be better monitored, while the BCH as a repository 
pertaining to information on LMOs102 has to be updated regularly by States parties.103 
The timely reporting of information especially for risk assessment of LMOs and the 
AIA procedure as well as the standardization of information are sorely needed. After 
the Compliance Committee reported on how to improve its supportive role where 
States parties are facing compliance difficulties, COP-MOP5 approved that where a 
State party has revealed compliance difficulties the Compliance Committee may 
make recommendations to the COP-MOP regarding measures of assistance.104 If the 
information within the national reports submitted by countries shows such 
difficulties, the Compliance Committee may also consider taking measures of 
assistance. A more active role of the Compliance Committee is most welcome to 
ensure effective national reporting on the implementation of obligations. One of the 
reasons for the persistent low rate of implementation is said to be related to the 
fast-changing landscape of biotechnology and countries’ shifting interests. The 
number of States exporting GMOs tends to increase with an inevitable influence on 
their decisions regarding transboundary movements of GMOs.105  
                                        
100  A compliance mechanism under an international environmental treaty is normally devised to help 
States parties to fulfil their obligations and deals with non-compliance; Secretariat of the CBD 
Report of the Compliance Committee Under the Cartagena Protocol on Biosafety COP-MOP5 
2010. 
101 See a 33, which requires parties to monitor the implementation of their obligations under the 
protocol and to report to the COP on the related measures taken. 
102  The BCH was set up also to facilitate the exchange of information on LMOs and assist parties to 
better comply with their obligations under the protocol. Global access to a variety of scientific, 
technical, environmental, legal and capacity building information is provided in all 6 of the UN 
languages. See CBD date unknown http://bch.cbd.int/protocol/cpb_art20.shtml; Smits and 
Zaboroski 2001 Asper Rev Int'l Bus & Trade L 99. 
103 The number of clearing house postings appears to lag far behind actual approval practices. 
Redick 2007 Colo J Int'l Envtl L & Pol'y 66. 
104 International Institute for Sustainable Development et al 2010 www.iisd.ca/vol09/ 
enb09533e.html. 
105 See Secretariat of the CBD 2012 www.iisd.ca/biodiv/bs-copmop6/. 
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4.5 GMO-related disputes settled mainly under the trade settlement 
dispute mechanism  
The CBD dispute settlement mechanism, the WTO dispute settlement mechanism or 
a voluntary private sector compensation mechanism known as the "Compact"106 are 
available to affected parties when there are GMO-related claims at the international 
level. Article 27(5) of the CBD states that its provisions on dispute settlement apply 
also to issues relating to one of its protocols, with possible recourse to the 
International Court of Justice or arbitration. When there is a damage resulting from 
a transboundary movement of LMOs that started after the entry into force of the 
Nagoya SP, the State party in whose jurisdiction the transboundary movement was 
made may apply domestic liability and redress procedures. It should be pointed out 
that pending the entry into force of the Nagoya SP, affected parties in GMO-related 
disputes may still use existing domestic liability procedures if adequate liability and 
redress rules are provided. If the damage has affected several States, the affected 
parties need to agree on which domestic liability procedures will apply. Only claims 
in relation to damage resulting from the transboundary movements of LMOs may be 
referred to the CBD’s dispute settlement mechanism and not those of the broader 
categories of GMOs. In practice, although the CBD provides for a dispute settlement 
mechanism, disputes pertaining to the trade of GMOs have been referred to the 
WTO dispute settlement mechanism.107 The WTO dispute settlement system was 
chosen by the affected parties in the dispute on the GM commodities’ exports which 
involved States that are not parties to the Cartagena Protocol.108 As for the dispute 
                                        
106  A redress mechanism initiated by six of the biggest biotechnological firms, namely BASF, Bayer 
CropScience, Dow AgroSciences, DuPont, Monsanto and Syngenta, which became operational in 
2010.  See the Compact’s website at The Compact date unknown www.biodiversitycompact.org/. 
See the acknowledgement of the Conference of parties to the Cartagena Protocol with regard to 
the existence of the Compact. Decision BS-V/11 COP-MOP 5 CBD 2010 
www.cbd.int/mop5/documents/. 
107  See the biotechnological products’ dispute between the EU and the US, Canada and Argentina 
(WTO - European Communities – Measures Affecting the Approval and Marketing of Biotech 
Products) and the canned tuna dispute between Egypt and Thailand (WTO Egypt - Import 
Prohibition on Canned Tuna with Soybean Oil). The WTO dispute settlement bodies have more 
than 30 cases to deal with per year and had had more than 400 cases by November 2009 
(Carreau and Juillard Droit International Économique 105) compared to the CBD dispute 
settlement system which has never dealt with any case yet (Ferraud-Ciandet Protection de la 
Santé 147). 
108  In this dispute, only the EU is a party to both the CBD and the Cartagena Protocol while 
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on the prohibition of the import of canned tuna with allegedly GM soybean oil 
between Egypt and Thailand, both countries are States parties to the CBD and the 
Cartagena Protocol, yet the complaint was referred to the WTO dispute settlement 
body.109 Egypt took into account some of Thailand’s claims and Thailand decided not 
to continue the dispute settlement proceedings any further. The WTO Committee on 
Trade and Environment (CTE) stated that while WTO members have the right to 
choose to bring a dispute to the WTO dispute settlement mechanism, WTO members 
which are also parties to the Cartagena Protocol should not undermine the 
obligations they accepted under this MEA.110 Consequently, if a dispute arises 
between WTO members which are also parties to the Cartagena Protocol over the 
use of trade measures they are applying pursuant to this protocol, they should 
consider trying to resolve it under the CBD settlement mechanism.111 However, 
future disputes on the transboundary movements of GMOs involving trade aspects 
are also not likely to be settled under the CBD dispute settlement mechanism.  
Since 2010 States may choose to settle claims regarding transboundary damage by 
LMOs under the "Compact" if the damage is caused by one of the GM products of 
the six major plant biotechnology companies. The "Compact" was elaborated by 
these GM companies with regard to damage caused to biological diversity by one of 
their biotech-derived products. If a claim against a Compact member cannot be 
settled, the matter can be resolved by way of arbitration under the aegis of the 
Permanent Court of Arbitration.112 This mechanism provides for contractual liability 
between importers and exporters. However, transboundary damage may affect 
parties who are not in a contractual relationship, especially in cases of the 
unintentional or illegal release of LMOs or in areas beyond national jurisdiction.   
                                                                                                                          
Argentina and Canada are parties to the CBD but not to the Cartagena Protocol. The US is not a 
member of either the CBD or the Cartagena Protocol. See CBD date unknown 
www.cbd.int/convention/parties/list/#tab=1. 
109  See the list of parties to the CBD and the Cartagena Protocol at CBD date unknown 
www.cbd.int/convention/parties/list/#tab=1. 
110  WTO Report of the CTE 1996 par 178. 
111  WTO Report of the CTE 1996 par 178. 
112  Either recourse under the Compact or a remedy under an otherwise applicable law but no double 
or multiple recoveries is allowed. See The Compact date unknown www.biodiversitycompact.org/ 
about/principles. 
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5 Conclusion 
The biosafety framework under the Cartagena Protocol represents the first attempt 
by governments to agree upon a binding global regime with a baseline of legal 
controls on the import and export of LMOs (and not all categories of GMOs). This 
protocol is also said to address risks associated with biotechnology in a manner 
conducive to its productive development and use.113 This global regime needs to be 
translated into national legal regimes and is a floor rather than a ceiling of biosafety 
regulation.114  
In spite of all the conflicts on the setting up of a stringent biosafety international 
framework due to its impact on the international trade of GMOs, this framework 
pertains not only to trade aspects but also to transboundary movements of GMOs for 
non-trade purposes. Transboundary movements of GMOs for trade purposes and for 
non-trade purposes must be clearly distinguished during discussions at the 
international level. 
This paper makes recommendations in relation to the key issues and concerns 
identified in the international biosafety framework: 
It is unclear whether some categories of LMOs such as nutraceuticals and 
biopharmaceuticals are covered by the Cartagena protocol. The need for a 
consensus on an international identification system for GM products with a 
harmonised threshold of GM content is highlighted. The implementation of the 
protocol must be better monitored to ensure that States parties comply with their 
obligations. A better monitoring of illegal movement of GMOs considered as 
hazardous (pathogenic GM micro-organisms) for public health or security 
(bioterrorism) is sorely needed.115 Since different national standards result in a less 
efficient international biosafety system, the harmonisation of national biosafety 
regulation is important. Harmonisation strategies need to be ensured by competent 
                                        
113  Hagen 2000 Geo Int'l Envtl L Rev 699. 
114  Hagen 2000 Geo Int'l Envtl L Rev 698. 
115  Bioterrorism is a threat to food security and targets principally the cultivation of agricultural 
products, animals, food products at all stages of the food chain. Ferraud-Ciandet Protection de la 
Santé 76.  
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international bodies based on international agreements instead of private actors with 
vested interests. The harmonisation of identification and traceability standards, risk 
assessment and risk management standards, and the communication of information 
on biotechnological risks must be reached with inter-State cooperation. NBFs in 
general seek to balance importer and exporter interests more than to comply with 
the Cartagena Protocol’s requirements. Consensus is sorely needed on the scope and 
interpretation of socio-economic considerations.  
The key issues and concerns identified relate generally to the compromises made by 
the negotiators of the Cartagena Protocol with a view to building consensus. 
Remedies to these shortcomings and the full compliance of States parties with this 
protocol’s requirements will depend largely on the fast-changing landscape of 
biotechnology, different countries’ interests, and different degrees of scientific 
knowledge on the effects of GMOs on the environment, human health and animal 
health. 
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